Vincerx Pharma (VINC)
(Real Time Quote from BATS)
$0.65 USD
-0.03 (-4.45%)
Updated Jul 17, 2024 12:02 PM ET
3-Hold of 5 3
F Value A Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VINC 0.65 -0.03(-4.45%)
Will VINC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VINC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VINC
Vincerx Pharma (VINC) Moves to Buy: Rationale Behind the Upgrade
Vincerx (VINC) Tumbles on Results From Cancer Therapy Study
VINC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VINC
12 Health Care Stocks Moving In Thursday's After-Market Session
Analysts Conflicted on These Healthcare Names: Cerevel Therapeutics Holdings (CERE), Cullinan Management (CGEM) and Vincerx Pharma Inc (VINC)
Vincerx Pharma GAAP EPS of -$0.58
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
VINC Stock Earnings: Vincerx Pharma Misses EPS for Q1 2024